BioSpace News Archive

BD, a leading global medical technology company, announced that Christopher DelOrefice has been named executive vice president and chief financial officer, effective Sept. 6, 2021.

Aditxt, Inc. today announced a partnership with Great Lakes Medical Laboratory, Inc. to offer its AditxtScore™ for COVID-19 throughout the State of Michigan.

Swing Therapeutics announced today that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to the company’s digital therapeutic for the management of fibromyalgia.

ChromaCode, Inc.today announced that Patrick Balthrop, Sr. and Kevin O’Boyle have joined the company’s Board of Directors.

Dyadic today announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic’s lead COVID-19 vaccine candidate, DYAI-100.

Advanced BioMatrix is adding to their extensive catalog of extracellular matrix proteins by providing iMatrix recombinant Laminin-511, Laminin-411 and Laminin 221.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has entered into a research agreement for a Phase 1 safety and pharmacokinetic study with its flagship product avenanthramide.

Capacity, an AI-powered support automation platform, today announces its partnership with Citeline Connect, the all-in-one clinical trial recruitment platform developed by Informa Pharma Intelligence.

1upHealth, a trusted FHIR® platform for health data interoperability, announced today that it is offering health plans free baseline testing to determine if their Patient Access application programming interface (API) is connecting to third-party developers as required by the Centers for Medicare and Medicaid Services (CMS) Rule.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that the company will host one-on-one investor meetings at the following investor conferences: